Financhill
Back

GlycoMimetics Quote, Financials, Valuation and Earnings

GlycoMimetics Price Quote

$0.26
-0.01 (-2.48%)
(Updated: May 13, 2024 at 2:30 PM ET)

GlycoMimetics Key Stats

Sell
13
GlycoMimetics (GLYC) is a Sell

Day range:
$0.26 - $0.28
52-week range:
$0.26 - $3.53
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.45%

Volume:
4.3M
Avg. volume:
2.7M
1-year change:
-84.85%
Market cap:
$17.2M
Revenue:
$10K
EPS:
$-0.58

How Much Does GlycoMimetics Make?

Data Unavailable

Is GlycoMimetics Growing As A Company?

Data Unavailable

GlycoMimetics Stock Price Performance

  • Did GlycoMimetics Stock Go Up Last Month?
    GlycoMimetics share price went down by -89.12% last month
  • Did GLYC's Share Price Rise Over The Last Year?
    GLYC share price fell by -84.85% over the past 1 year

What Is GlycoMimetics 52-Week High & Low?

GlycoMimetics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy GlycoMimetics?

  • How Much Debt Does GlycoMimetics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does GlycoMimetics Have?
    Cash and short term investments quarterly total is $41.8M
  • What Is GlycoMimetics’s Book Value Per Share?
    Book value per share is 0.60

Is GlycoMimetics Cash Flow Positive?

  • What Is GLYC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$34.9M
  • What Is GlycoMimetics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $28.8M
  • What Is GlycoMimetics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$21.4K

GlycoMimetics Return On Invested Capital

  • Is Management Doing A Good Job?
    GLYC return on invested capital is -75.34%
  • What Is GlycoMimetics Return On Assets?
    ROA measures how assets are converting to revenues and is -65.64%
  • What Is GLYC Return On Equity?
    ROE is a measure of profitability and is -75.34%

GlycoMimetics Earnings Date & Stock Price

GlycoMimetics Competitors

  • Who Are GlycoMimetics's Competitors?
    Below is a list of companies who compete with GlycoMimetics or are related in some way:
    • Altimmune Inc (ALT)
    • Amicus Therapeutics Inc (FOLD)
    • InfuSystems Holdings Inc (INFU)
    • Lyell Immunopharma Inc (LYEL)
    • Nanoviricides Inc (NNVC)

GlycoMimetics Dividend Yield

Data Unavailable

GlycoMimetics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -4.08%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 0.75
Upside from Last Price: 181.32%

Major Shareholders

  • How many GLYC shares are owned by institutional investors?
    40.5M GLYC shares are owned by institutional investors
  • How many GLYC shares are owned by insiders?
    2.2M GLYC shares are owned by insiders